Vireo Growth (VREOF) Change in Accured Expenses (2020 - 2025)
Vireo Growth's (VREOF) quarterly Change in Accured Expenses came in at $10.1 million in Q4 2025, up 747.1% year-on-year from $1.2 million in Q4 2024, and up 154.18% quarter-over-quarter from -$18.6 million in Q3 2025.
Vireo Growth (VREOF) Change in Accured Expenses (2020 - 2025) Analysis & Trends
Vireo Growth has disclosed Change in Accured Expenses across 6 years of filings, most recently posting $10.1 million for Q4 2025.
- Change in Accured Expenses for Q4 2025 came in at $10.1 million, up 747.1% year-over-year; the trailing twelve-month figure through Dec 2025 was -$8.7 million (down 462.65% YoY), and the FY2025 annual result was -$8.7 million, down 462.65% from the prior year.
- Change in Accured Expenses came in at $10.1 million for Q4 2025 at Vireo Growth, up from -$18.6 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $10.1 million in Q4 2025 to a low of -$18.6 million in Q3 2025.
- The 5-year median for Change in Accured Expenses is $607847.0 (2024), against an average of -$284488.8.
- Peak annual rise in Change in Accured Expenses reached 932.47% in 2025, while the deepest fall reached 797218.55% in 2025.
- Vireo Growth's Change in Accured Expenses stood at $5.2 million in 2021, then sank by 160.13% to -$3.1 million in 2022, then rose by 25.38% to -$2.3 million in 2023, then jumped by 150.95% to $1.2 million in 2024, then soared by 747.1% to $10.1 million in 2025.
- The last three Change in Accured Expenses figures came in at $10.1 million (Q4 2025), -$18.6 million (Q3 2025), and -$2.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 10.02 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 23.00 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.08 Mn |
| Dec 31, 2025 | 10.08 Mn |
| Sep 30, 2025 | -18.61 Mn |
| Sep 30, 2025 | -18.61 Mn |
| Jun 30, 2025 | -1.99 Mn |
| Jun 30, 2025 | -1.99 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | -2,334.00 |
| Sep 30, 2024 | -2,334.00 |
| Jun 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 174,340.00 |
| Mar 31, 2024 | 174,340.00 |
| Dec 31, 2023 | -2.34 Mn |
| Dec 31, 2023 | -2.34 Mn |
| Sep 30, 2023 | -1.48 Mn |
| Sep 30, 2023 | -1.48 Mn |